News for 'CTIX' - (Cellceutix to Pursue Significant

New Post Public Reply Private Reply Replies (2) Message Board

Nov 4, 2013 at 7:15 AM

News for 'CTIX' - (Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin)

BEVERLY, MA, Nov 04, 2013 (Marketwired via COMTEX) -- Cellceutix Corporation
(OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company
developing innovative therapies in oncology, dermatology, and antibiotic
applications, is pleased to inform shareholders that the Company is conducting
experiments on Brilacidin(TM), its lead antibiotic compound, for ophthalmic
infections, including keratitis and conjunctivitis. Cellceutix estimates the
market potential for these indications well in excess of $1 billion and has its
antibiotic team expanding upon the significant amount of preclinical research
that has been conducted on Brilacidin for these conditions.

Prior to the Cellceutix acquisition of PolyMedix in September, lab studies
conducted at the Charles T. Campbell Ophthalmic Microbiology Laboratory at the
University of Pittsburgh demonstrated the safety, tolerability and broad
activity of Brilacidin against clinically important Gram-positive and
Gram-negative pathogens, including drug-sensitive and drug-resistant clinical
isolate strains of ocular infections.

Pharmacokinetic studies were conducted at Iris Pharma, a Contract Research
Organization based in France, showing that Brilacidin has a high residence time
on the surface of the eye with negligible systemic exposure. This indicates that
effective therapeutic concentrations of Brilacidin can be maintained in the eye
with infrequent treatments.

As a defensin-mimetic, Brilacidin is a completely novel class of antibiotics and
a platform for a broad spectrum of indications in an area of urgent need for new
drugs. Topical ophthalmic anti-infective drugs that are used today for keratitis
and conjunctivitis have serious limitations due to bacterial resistance and
serious side effects. For example, although exclusive of topical uses of
fluoroquinolones for eye and ear infections, the U.S. Food and Drug
Administration in August required that drug labels and Medication Guides for all
systemic fluoroquinolone antibacterial drugs be updated to describe the
potential serious side effect of peripheral neuropathy.

"The Brilacidin ocular data is highly exciting. Our new research program
focusing on ocular drugs is the next step in expanded uses of Brilacidin that we
believe will develop into a blockbuster antibiotic drug franchise," said Dr.
Krishna Menon, Chief Scientific Officer at Cellceutix. "We have a litany of
clinical and preclinical data on Brilacidin. Our research staff is currently
growing epithelial cells for testing so that we can formulate Brilacidin as a
topical solution with efficient penetration of the epithelium to maximize
clinical results."

"We are going to continue aggressively moving forward with Brilacidin as the
current biotechnology environment is desperate for new therapeutics," added Leo
Ehrlich, Chief Executive Officer at Cellceutix. "Reuters reported only yesterday
that Swiss drugmaker Roche is poised to get back into antibiotics because of a
novel drug that they want to develop to tackle drug-resistant bacteria. Simply,
a novel drug has phenomenal sales potential. Johnson & Johnson's Levaquin was
generating $1.3 billion in sales before it came off patent. Cubist's Daptomycin
for ABSSSI only comprised 8 percent of total doses, yet controlled approximately
82 percent of total sales in that market. The majority of approved antibiotics
today are legacy drugs or variations of them for which resistance is constantly
evolving. Our plan is to establish Brilacidin as the next generation antibiotic.
It has opened a door to a multi-billion-dollar pathway and we are not just
looking at it, we are part way through it and moving as quickly as possible to
establish a leadership position."

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company
under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical
company developing innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world class portfolio of compounds
and is now engaged in advancing its compounds and seeking strategic
partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1
clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth
Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce
activation of p53, often referred to as the "Guardian Angel Gene" due to its
crucial role in controlling cell mutations. Cellceutix is planning a Phase 2
clinical trial with its novel compound Brilacidin-OM for the prevention and
treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has
shown in the laboratory to reduce the occurrence of severe ulcerative oral
mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug
Prurisol is being readied for a Phase 2/3 clinical trial at sites in the U.S.
and Europe. Prurisol is a small molecule that acts through immune modulation and
PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is set to begin a
Phase 2b trial in the first half of 2014 for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. Brilacidin has the potential to be a
single-dose therapy for multi-drug resistant bacteria or a dosing regimen that
is shorter than currently marketed antibiotics. Cellceutix has formed research
collaborations with world renowned research institutions in the United States
and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical
Center, and the University of Bologna. More information is available on the
Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause Cellceutix's
actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. Cellceutix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements are Cellceutix's need for, and the
availability of, substantial capital in the future to fund its operations and
research and development; including the amount and timing of the sale of shares
of common stock to Aspire Capital; the fact that Cellceutix's compounds may not
successfully complete pre-clinical or clinical testing, or be granted regulatory
approval to be sold and marketed in the United States or elsewhere. A more
complete description of these risk factors is included in Cellceutix's filings
with the Securities and Exchange Commission. You should not place undue reliance
on any forward-looking statements. Cellceutix undertakes no obligation to
release publicly the results of any revisions to any such forward-looking
statements that may be made to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events, except
as required by applicable law or regulation.

Contact:

INVESTOR AND MEDIA CONTACT:

Cellceutix Corp.

Leo Ehrlich

(978) 236-8717

Email Contact

SOURCE: Cellceutix

(C) 2013  Marketwire L.P.  All rights reserved.

-0-

SUBJECT CODE:     Pharmaceuticals and Biotech:Biotech

                  Pharmaceuticals and Biotech:Trials

                  Pharmaceuticals and Biotech:Equipment and Supplies

                  Pharmaceuticals and Biotech

rugs

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Graywind Redefines Flexibility with New Blinds 2.0

Sliding blinds—who knew they'd stir up such a fuss? But here comes Graywind, rolling out their Manual Sliding Track Blinds 2.0, and it's clear they're turning heads in Santa Clara and beyond. This ain't your grandma's drapery setup. We're talking about a sleek, mid-to-premium panel-track system designed to cater to modern living spaces and architectural whimsy. It's...

Decoding Historic Home Buys: Tips for New Owners

Realities Behind the Rustic Facade Picture this: you’re standing in front of a crumbling beauty with crown molding and character oozing from its very walls. Now what? It's easy to get swept away by the allure of a historic home, but there's gritty work to be done under those charming facades. Enter Debi Beiland of Limestone Properties over in Maysville, KY. She’s got...

China Expo Spotlights AI's Role in Future Electronics

AI Tech Takes Center Stage in Qingdao Kicking off the week, the 2026 China International Consumer Electronics Exposition unfolds its grand spectacle in Qingdao. Now, we're not just talking your average tech fare here—this is a heavyweight event with over 300 titans from 12 countries sprawling across a hefty 60,000 square meters. And those are numbers that make people...

Tech Job Market Surges: 86,000 Hires in August Boost

Tech Job Growth Defies Corporate Layoffs Job markets in the tech world are hotter than a two-dollar pistol. Despite seeing some layoffs in tech firms, the demand for skilled tech workers is still booming. You got tech companies tightening the bolts, laying off around 14,700 folks, but here's the kicker: overall tech employment shot up with 86,000 new jobs in August....

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Solomon e3 Halves Cloud Costs with NexQloud Shift

Ever feel like you're drowning in an unnecessary cloud bill? Well, Solomon e3 did something about it. They chopped over half of their cloud spending after partnering with NexQloud. This isn't just an old-school belt-tightening; it's a full-on digital revamp after a deep-dive into their IT finances. Saving Pennies and Dollars with Smart Moves You'd think an energy company...

Carestream's Enhanced DRX-LC: Imaging Game Changer

Rethinking Long-Length Imaging with Carestream The medical imaging sector just got a shot in the arm with Carestream Healthcare International's latest leap in technology. The DRX?LC Detector is not just a fancy update — it's a full-on revolution for long?length imaging. Forget the old days of piecing multiple exposures together, because this innovation simplifies...

HoneyNaps Unveils Wireless PSG: Sleep Testing Revolution

Tearing Down the Wired Wall in Sleep Studies Well, here's a switch-up that's long overdue in the world of sleep disorders diagnostics. It looks like HoneyNaps has figured out how to ditch the tangled mess that is traditional polysomnography (PSG) with their new creation—a wireless PSG system, and I gotta say, I'm liking the sound of that. If you've ever been strapped to...

JIMMY's Nespure N9: Innovating Coffee and Clean Water

Unpacking JIMMY's Latest Innovation at IFA Every now and then, something comes along that makes you think, "Why didn't I think of that?" Well, JIMMY just hit that nail square on the head with its latest concoction—the Nespure N9. Debuting at the IFA 2026 in Berlin, this little gizmo combines water purification with coffee brewing, all from a modestly-sized countertop...

Vobile Teams Up with UNN for AI Factories in Brunei

Delving into Vobile's Latest Strategic Move Vobile, a heavyweight in digital content protection based out of Santa Clara, California, has hit the headlines with a new venture. They've inked a strategic cooperation and commercial agreements with Unified National Networks (UNN) of Brunei Darussalam to construct AI factories. This ain't your run-of-the-mill news, folks. It's...